July 23 (Reuters) - Precision BioSciences Inc DTIL.O:
PRECISION BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR PBGENE-DMD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
PRECISION BIOSCIENCES INC - CLINICAL DATA FOR PBGENE-DMD EXPECTED IN 2026
Source text: ID:nBw9GS74La
Further company coverage: DTIL.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.